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Background: Use of real-time continuous glucose monitoring (rtCGM) systems has been shown to be a low-pain, safe, and
effective method of preventing hypoglycemia and hyperglycemia in people with diabetes of various age groups. Evidence on
rtCGM use in infants and in patients with conditions other than diabetes remains limited.
Objective: This case study describes the off-label use of rtCGM and the use of an open-source app for glucose monitoring in
a newborn with prolonged hypoglycemia secondary to transient congenital hyperinsulinism during the perinatal period.
Methods: The Dexcom G6 rtCGM system (Dexcom, Inc) was introduced at 39 hours of age. Capillary blood glucose checks
were performed regularly. In order to benefit from customizable alert settings and detect hypoglycemic episodes, the open-source
rtCGM app xDrip+ was introduced at 9 days of age.
Results: Time in range (45-180 mg/dL) for interstitial glucose remained consistently above 90%, whereas time in hypoglycemia
(<45 mg/dL) decreased. Mean glucose was maintained above 70 mg/dL at 72 hours of life and thereafter. Daily sensor glucose
profiles showed cyclic fluctuations that were less pronounced over time.
Conclusions: While off-label use of medication is both common practice and a necessity in newborn infants, there are few
examples of off-label uses of medical devices, rtCGM being a notable exception. Real-time information allowed us to better
understand glycemic patterns and to improve the quality of glycemic control accordingly. Severe hypoglycemia was prevented,
and measurement of serum levels of insulin and further lab diagnostics were performed much faster, while the patient’s individual
burden caused by invasive procedures was reduced. Greater customizability of threshold and alert settings would be beneficial
for user groups with glycemic instability other than people with diabetes, and for hospitalized newborn infants in particular.
Further research in the field of personal and off-label rtCGM use, efficacy studies evaluating the accuracy of low glucose readings,
and studies on the differences between algorithms in translating raw sensor data, as well as customization of commercially
available rtCGM systems, is needed.
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Introduction
Transient and persistent congenital hyperinsulinism (CHI) are
rare diseases affecting 1 to 2 in 50,000 newborns. At least 12
genetic defects have been identified that result in dysregulated
and increased insulin secretion and subsequently severe
hypoglycemia, which may be transient or persistent [1,2].
Frequent hypoglycemia is a potentially life-threatening
complication of CHI and may lead to permanent brain damage,
which may present in developmental delay and mild to severe
neurocognitive difficulties such as deficits in attention, memory,
and visual and sensorimotor functions in children with CHI
[3,4]. Furthermore, prolonged hospitalizations and intense
medical regimes pose a constant psychological burden to infants
and children with CHI and their caregivers, limiting their
participation in social life, kindergarten, and school [2,5].
Therefore, prevention of hypoglycemia is the main treatment
goal in patients with CHI [5,6]. Therapeutic regimens are
complex and depend on the underlying genotype and phenotype.
Treatment options today include regular feeding,
pharmacotherapy with diazoxide, somatostatin analogues and
glucagon for diffuse forms, and surgery for focal variants of
CHI [6].
Real-time continuous glucose monitoring (rtCGM) and
intermittently scanned continuous glucose monitoring (isCGM),
as designed for and commonly used by people with diabetes,
provide information on current interstitial glucose levels and
trends, and alert the user of current or predicted hypoglycemia
and hyperglycemia as well as rapid changes in glucose levels.
With regular measurements up to every 5 minutes, they also
provide statistics on time spent in hypoglycemia, in
hyperglycemia, and within range.
Evidence on rtCGM use for glycemic management in neonates
is limited, and there is no evidence of calibration-free rtCGM
systems in infants so far. Benefits with respect to glycemic
control [7] and less procedural pain [8] have been previously
described for very low-birth-weight preterm infants in a
feasibility study. Furthermore, a study found continuous tissue
glucose monitoring to be helpful to identify infants at risk for
metabolic instabilities [9]. However, knowledge remains limited
for infants and other patient groups at risk of hypoglycemia so
far [10,11].
The off-label use of rtCGM in children with CHI was first
described in 2004 [12]. Further studies describe rtCGM and
isCGM as safe, effective, convenient, and less painful methods
of glucose monitoring in CHI patients that provide helpful
information for therapeutic decisions [13,14]. Caregivers found
the indication of glucose trends to be helpful, felt more confident
in everyday management of the condition, and felt less worried
about the occurrence of asymptomatic hypoglycemia [12,14].
However, older rtCGM/isCGM systems were reported to have
limited accuracy, especially for hypoglycemic levels, and
therefore not recommended to completely replace capillary
blood glucose (CBG) testing, but rather seen as an adjunctive,
beneficial therapy [13,15].
To our knowledge, this case study describes the first use of the
rtCGM app xDrip+ in a hospital and intensive care unit (ICU)
setting and the first off-label use of rtCGM in a newborn with




A male infant was delivered full term with a birth weight of
3575 g. An emergency cesarean delivery was performed in
response to fetal heart rate monitoring indicating fetal distress.
The infant presented with bradypnea, floppiness, and sporadic
myoclonic jerks and was transiently treated with noninvasive
positive pressure resuscitation. A CBG level of 12 mg/dL was
detected at 60 minutes of life. Despite feeding attempts and
buccal administration of 40% dextrose gel, the blood glucose
level decreased further to 1 mg/dL at 120 minutes of life. The
patient was started on continuous intravenous glucose and
admitted to the neonatal intensive care unit (NICU) for further
diagnostics and treatment. The continuous intravenous glucose
administration required to maintain blood glucose levels above
50 mg/dL was incrementally increased from 8 mg/kg/min to
over 18 mg/kg/min. This required placement of a central venous
line at 37 hours of age to allow for administration of hypertonic
glucose solutions. In addition, the infant received copious enteral
feedings.
The child’s father and the paternal uncle were both reported to
have experienced transient postnatal hypoglycemia, requiring
hospitalization for 3 weeks after birth. The child’s father
reported having often experienced mild hypoglycemia symptoms
such as hunger and craving for sweets when fasting. However,
blood glucose levels were reported to be within normal range
during routine checkups as an adult. There was no history of
diabetes in either of the parents, and screening for gestational
diabetes during pregnancy was reported to be negative.
However, the paternal grandmother was reported to have been
diagnosed with type 1 diabetes at 7 years of age.
Genetic Testing
Next-generation sequencing (quality level type A; SureSelect
XT, Custom Constitutional Panel 17 Mb; Agilent Technologies,
Inc) of a CHI panel, including ABCC8 (GenBank
NM_000352.4), HADH (GenBank NM_005327.4), HNF4A
(GenBank NM_175914.4), KCNJ11 (GenBank NM_000525.3),
KMT2D (GenBank NM_003482), and UCP2 (GenBank
NM_003355.2), was performed by Labor Berlin, Germany.
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To reduce the frequency of capillary blood samples and estimate
the right moment for further lab diagnostics, the Dexcom G6
rtCGM system (Dexcom, Inc) was introduced for off-label use
at 39 hours of age. In addition, CBG checks were performed
regularly, at least 3 times per day (Multimedia Appendix 1).
All decisions concerning the therapeutic regimen were based
on confirmatory CBG tests. Sensors were placed at the lateral
sides of thighs or upper arms (Figures 1 and 2) where enough
fat and muscle tissue were present. Sensors were replaced every
7 days.
During the first week, the sensor was paired with a Dexcom G6
handheld device with customizable alert settings; however, the
urgent low glucose alarm threshold at a glucose level of 55
mg/dL, which was frequently passed in this neonate but does
not meet the requirements in neonates within the first week of
life, could not be further reduced. Furthermore, glucose levels
below 40 mg/dL could not be further differentiated. In order to
benefit from customizable alert settings and include potential
hypoglycemic levels below 40 mg/dL, the informed decision
was made to pair the sensors with the caregivers’ personal
Android phone using the app xDrip+.
Figure 1. Upper thigh as a suitable rtCGM application site in neonates.
Figure 2. Upper arm as a suitable rtCGM application site in neonates.
Specifics of the xDrip+ Algorithm
xDrip+ [16] is an open-source product with no regulatory
approval that allows the user to choose between the approved
native algorithm, which runs on the Dexcom G6 transmitter for
translating uncalibrated transmitter data into interstitial glucose
level estimations, and its own algorithm, which approximates
a linear function using the method of weighted least squares
regression by weighting calibration points based on their value,
sensor and calibration age, the current glucose trend, a variability
heuristic, and other factors. Furthermore, low glucose alarm
settings are fully customizable. In this case study, the xDrip+
algorithm was used with a minor modification that allowed
sensor glucose levels below 40 mg/dL to be received, although
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accuracy was expected to be limited in this range. Alerts were
set at 45 mg/dL for low sensor glucose levels and at 140 mg/dL
for high sensor glucose levels.
Data Analysis
For the first 7 days of sensor data, rtCGM readings were
exported from the Dexcom handheld device using the Dexcom
Clarity software. For the following days when xDrip+ was used,
sensor data was exported through the built-in data export
function in the xDrip+ app. For the analysis of sensor data, we
computed statistical properties (arithmetic mean and standard
deviation) in the programming language Python 3.7.
Furthermore, time in hypoglycemia and time in range were
calculated as follows:
As there is currently no standardized definition for treatment
consequences in response to low and high glucose levels in
neonates, but their physiological range tends to be lower than
in older individuals [9], sensor glucose in range was defined by
a lower threshold of 45 mg/dL (2.5 mmol/L) and an upper
threshold of 180 mg/dL (10 mmol/L). Therefore, time in
hypoglycemia was calculated based on sensor readings under
45 mg/dL (2.5 mmol/L).
Results
Diagnostic Workup
The infant responded well to a single subcutaneous injection of
30 µg/kg of glucagon (GlucaGen Hypokit; Novo Nordisk A/S).
Therefore, a glycogen storage disease was unlikely to be the
underlying condition and congenital hyperinsulinism was
suspected. According to CHI treatment guidelines [6], a
continuous subcutaneous glucagon infusion was initiated at 64
hours of age and gradually increased (up to 27.2 µg/kg/h)
(Multimedia Appendix 1). Glucagon dosage was adjusted
(increased or lowered) according to rtCGM glucose using
defined thresholds for each action; thus, the continuous glucose
infusion could be gradually reduced and completely terminated
by 13 days of age. In the following days, glucagon
administration was gradually decreased and completely
terminated 17 days of age. That treatment algorithm successfully
prevented occurrence of any symptomatic hypoglycemia (eg,
seizures, hypothermia, hypotonia, bradypnea). No other drugs
such as diazoxide or lanreotide were administered.
Initial hypoglycemia screening revealed hyperinsulinemia with
no ketonemia present (blood glucose 29 mg/dL, insulin 9.03
mU/L, C-peptide 2.34 µg/L). After terminating the intravenous
glucose and the subcutaneous glucagon infusion and with
increasing improvement of oral feeding and hence regular and
reliable enteral glucose uptake, no new hypoglycemic episodes
occurred between days 17 and 20. Consequently, we suspected
normalization of insulin secretion, which was substantiated by
an analysis after a strict fasting period of 6.5 hours (blood
glucose 86 mg/dL, insulin 1.5 mU/L, C peptide 0.54 µg/L,
ketone bodies 0.4 mmol/L) on day 20. With these results, we
were able to terminate rtCGM use and discharge the infant on
the same day in good health.
Genetic testing did not reveal any disease-relevant pathologic
variation in genes that are most frequently associated with CHI:
ABCC8 (GenBank NM_000352.4), HADH (GenBank
NM_005327.4), HNF4A (GenBank NM_175914.4), KCNJ11
(GenBank NM_000525.3), and UCP2 (NM_003355.2).
However, we detected a novel, highly conserved, and
heterozygous missense variant in the KMT2D gene (c.3976C>T,
R1326W), which was interpreted as a pathogenic variant within
this analysis and might be causative in this particular case of a
Kabuki syndrome with predominantly transient, congenital
hyperinsulinism [17,18].
Glycemic Outcomes
Time in range (sensor glucose readings between 45 and 180
mg/dL or 2.5 and 10 mmol/L) remained consistent above 90%,
whereas time in hypoglycemia (<45 mg/dL or <2.5 mmol/L)
decreased, and mean glucose was maintained above 70 mg/dL
or 3.8 mmol/L at 72 hours of life and after (Table 1). Daily
sensor glucose profiles (Multimedia Appendix 1) show cyclic
fluctuations exceeding 45 mg/dL (2.5 mmol/L) on most days
and occasionally 180 mg/dL (10 mmol/L). These cyclic
fluctuations were found to be less pronounced over time.
rtCGM readings were found to be mostly accurate compared to
CBG (Multimedia Appendix 1). Significant deviations (>15%)
occurred within the first 24 hours after a new sensor was placed.
After recalibration of the rtCGM, accuracy of rtCGM readings
was satisfactory (<15% deviations).
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Table 1. Analysis of rtCGM readings within the first 16 days of life in a neonate with transient CHI, including mean sensor glucose (SD), time in
hypoglycemia (defined as the percentage of sensor readings below 45 mg/dL), and time in range (defined as the percentage of sensor readings between
45 mg/dL and 180 mg/dL).
















aTIR: time in range.
bTIH: time in hypoglycemia.
Discussion
Principal Findings
This case study describes the use of a Dexcom G6 rtCGM
system in a neonate with transient CHI during the perinatal
period, using two different algorithms. The real-time information
provided by the rtCGM system allowed us to better understand
glycemic patterns of the underlying condition and to improve
the quality of glycemic control of our patient accordingly.
Severe hypoglycemia was successfully prevented and
measurement of serum levels of insulin and further lab
diagnostics were performed much faster, while the patient’s
individual burden caused by invasive procedures could be
reduced.
To our knowledge, this is the first report on the use of
open-source apps for glucose monitoring such as xDrip+ in a
hospital and ICU setting, as well as the first study reporting an
off-label use of a precalibrated rtCGM system in a neonate.
Furthermore, we described the first use of rtCGM in an infant
with transient CHI in the most critical phase during the first
days of life.
While off-label use of medication is both common practice and
a necessity in newborn infants, there are few examples of
off-label uses of medical devices, rtCGM being a notable
exception [7,8,19-24]. CBG tests are the current standard of
care in the management of neonatal hypoglycemia. However,
CBG has notable limitations. Heel pricks, associated with pain,
are required every time a blood sample is taken. Furthermore,
it provides only single point measurements without a continuous
profile on glucose trends, dynamics, and interactions with drugs
and meals. Conversely, rtCGM records any hypoglycemic
episode in a quantitative fashion, displays detailed
pharmacodynamics of single drugs, and consequently can help
to determine a drug’s long-term requirement. We assume that
rtCGM use could be extremely helpful in any hospital or home
setting and in this case, could help reduce the child’s risk for
neurological long-term complications [3,4,25]. Our experiences
with the presented case indicate that greater customizability of
threshold and alert settings would be beneficial for user groups
with glycemic instability other than people with diabetes, and
for hospitalized infants in particular. Further potential use cases
may include children of mothers with gestational diabetes,
children with metabolic disorders, children with neonatal
diabetes mellitus, preterm infants, and infants with difficulties
in enteral feeding.
Strengths and Limitations
It is important to note that although rtCGM provides information
about glucose dynamics and variability, these systems might
be less accurate when it comes to direct comparison with
point-of-care testing of blood glucose levels. In order to keep
invasive diagnostics for the patient reduced to a minimum, there
were not enough CBG data points available to allow for a robust
calculation of the mean absolute relative difference. This limits
our ability to evaluate the accuracy of rtCGM readings,
particularly of glucose levels <40 mg/dL. As rtCGM systems
correlate the electric signal of the sensor with interstitial glucose
concentrations in a linear fashion, they are not designed to detect
the low glucose levels that occur in newborn infants after birth.
Moreover, alert settings are not fully customizable to threshold
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values that seem reasonable to use in infants, who have a much
lower physiological glucose range compared to older children
and adults [9].
The app xDrip+, which was used in this case study, originates
from an online community of people living with type 1 diabetes.
The Android application package needed for setup, the app’s
source code, and instructions on how to install and use the app
are openly available on the internet. Recently, open-source
rtCGM apps such as xDrip+ for Android phones [16] and Spike
for Apple iOS [26] have become increasingly popular and are
used by thousands of people in the worldwide type 1 diabetes
community [27], especially by those living in countries where
commercial rtCGM systems are not accessible or not reimbursed
by the healthcare system [28]. Despite their popularity, so far
neither of the aforementioned open-source rtCGM apps have
been tested in clinical trials or been approved by a regulatory
body. The creators of these apps and the online community
around them publicly disclose that they should be used with
caution at all times and at one’s own risk. The controlled
environment of a NICU was an ideal setting to observe outcomes
and potential benefits of the off-label use while ensuring
minimal risk for the patient at the same time. We found that the
app was also a more suitable solution that best met the child’s
medical needs as well as healthcare professionals’ and the
caregivers’ expectations on relevant alarms in case of glucose
excursions. However, the safety and accuracy of xDrip+ as such
has not been systematically investigated so far, and its use has
only been described in conjunction with observational and
self-reported data from open-source automated insulin delivery
system users [29,30]. Further research on personal and off-label
rtCGM use and differences between native and alternative
algorithms in translating raw sensor data is needed, as well as
customization of commercially available rtCGM systems.
Conclusions
The use of rtCGM can be considered in neonatal patients at risk
of hypoglycemia, such as infants with transient or permanent
CHI, to reduce the frequency of blood glucose measurements
and focus them on potential decision-making points. However,
these devices have been designed to be used by people with
diabetes and are currently not approved for use in children
younger than 2 years of age. Other use cases, such as infants
with glycemic instability and other patients with rare conditions
that might benefit from continuous glucose monitoring, are
currently not being addressed sufficiently by the medical device
market. Further investigation on the use and accuracy of rtCGM
in wider patient groups, as well as further customization of
rtCGM systems, is needed to address unmet needs of wider
population groups.
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Multimedia Appendix 1
Daily profiles of sensor glucose and therapeutic management of a newborn with transient CHI. Sensor glucose readings [mg/dL]
are shown in blue, i.v. glucose distribution in green [mg/kg/min) and s.c. glucagon infusion in orange [µg/kg/h]. Low sensor
glucose threshold (45 mg/dL) is shown in red. Capillary blood glucose (CBG) measurements are marked in magenta.
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